Clinical trial finds existing drug dupilumab may treat rare GI disease eosinophilic gastritis
A clinical trial supported by the Rare Diseases Clinical Research Network (RDCRN) found that dupilumab, an existing drug, may be an effective treatment for eosinophilic gastritis (EoG), a rare gastrointestinal disease with no FDA-approved treatments. EoG causes chronic symptoms like vomiting, bloating, diarrhea, ulcers, and GI bleeding due to immune system overreaction in the digestive tract. The findings offer a potential new therapeutic option for patients with this rare condition.
18h ago5 min readenNews
Key quotes
People with EoG can experience chronic symptoms, such as vomiting, bloating, diarrhea, ulcers and GI bleeding.
Eosinophilic gastritis (EoG) — one rare GI disease — does not have any U.S. Food and Drug Administration (FDA)–approved treatments.
Food allergies can sometimes trigger ongoing inflammation in the digestive tract and lead to serious chronic disease.
You might also wanna read
A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
clinicaltrials.gov·8d ago
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
clinicaltrials.gov·1d ago
Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
clinicaltrials.gov·2d ago
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
ScienceDaily·13d ago
Biohacker Bryan Johnson Diagnosed with Incurable Autoimmune Gastritis
Bryan Johnson, the tech entrepreneur and longevity advocate known for his extreme $2 million/year health regimen, has been diagnosed with au
impactnews-wire.com·21h ago
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.